Facilitated "spin-out" technology from BioSante Pharmaceuticals, Inc. and co-Founded Cold Genesys, Inc.
LINCOLNSHIRE, Illinois (November 17, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX
today announced it sold to Cold Genesys, Inc. exclusive, worldwide
rights to develop and commercialize its oncolytic virus technology. The
technology includes CG0070, a replication-competent adenovirus that has
completed a Phase I clinical trial for treatment of superficial bladder
Cold Genesys, Inc
is a specialty pharmaceutical company that
focuses on fulfilling unmet medical needs in cancer treatment with a
present emphasis on bladder cancer. Based in Newport Beach, California,
Cold Genesys is a privately funded, early-stage company anticipating
global development of its technology.